{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:01:33Z","timestamp":1784808093389,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473266, 82160129"],"award-info":[{"award-number":["82473266, 82160129"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Gastric cancer, a leading global cause of cancer-related mortality, is frequently diagnosed at advanced stages with peritoneal metastasis, significantly limiting curative options. Current strategies integrate systemic chemotherapy, hyperthermic intraperitoneal chemotherapy (HIPEC), and targeted therapies, yet outcomes remain suboptimal. Claudin18.2, a tight junction protein overexpressed in 27.4\u201352% of gastric cancers, has emerged as a novel therapeutic target, with recent Phase III trials demonstrating survival benefits for Claudin18.2-targeted monoclonal antibodies in HER2-negative advanced disease. However, the synergy of HIPEC with Claudin18.2-targeted therapies remains unexplored. This study presents a case of Claudin18.2-positive advanced gastric adenocarcinoma with peritoneal metastasis treated with a multimodal regimen: HIPEC, systemic CapeOx chemotherapy, and Claudin18.2-targeted therapy (ASKB589). Following 12 cycles, imaging and tumor markers (CA125, CEA) normalized, enabling curative gastrectomy. At 893 days post-diagnosis, the patient remains disease-free (PFS\/DFS: 893\/573 days) on adjuvant capecitabine. Treatment-related toxicities (predominantly Grade 1\u20133 hematologic and gastrointestinal events) were manageable. This case highlights Claudin18.2 as an actionable biomarker and proposes a \u201clocal-systemic\u201d synergy model for peritoneal-metastatic gastric cancer. However, the absence of cytoreductive surgery and single-case limitations necessitate validation through randomized trials. Future research should prioritize biomarker-driven HIPEC protocols (e.g., nanoparticle-enhanced Claudin18.2-targeted delivery) and dynamic monitoring of Claudin18.2 expression during therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1641424","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:21:55Z","timestamp":1763446915000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Sequential HIPEC, Claudin18.2-targeted therapy, and CapeOx chemotherapy leading to resolution of peritoneal metastases and curative resection in gastric cancer: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Weidong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.0182","article-title":"Surgical management of gastric cancer: A review","volume":"157","author":"Li","year":"2022","journal-title":"JAMA surgery"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1010428317714626","DOI":"10.1177\/1010428317714626","article-title":"Progress in the treatment of advanced gastric cancer","volume":"39","author":"Song","year":"2017","journal-title":"Tumour biology: J Int Soc Oncodevelopmental Biol Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn.441530-20201116-00611","article-title":"Current status of diagnosis and treatment of gastric cancer peritoneal metastasis","volume":"24","author":"Zhang","year":"2021","journal-title":"Zhonghua wei chang wai ke za zhi = Chin J gastrointestinal surgery"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02867","article-title":"Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial","volume":"42","author":"Rau","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1186\/s12885-020-07601-x","article-title":"Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study","volume":"20","author":"Yu","year":"2020","journal-title":"BMC cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-017-0473-4","article-title":"Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer","volume":"10","author":"Singh","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz068","article-title":"Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma","volume":"49","author":"Rohde","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13919","article-title":"Clinical implications of claudin18.2 expression in patients with gastric cancer","volume":"39","author":"Baek","year":"2019","journal-title":"Anticancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-022-00385-1","article-title":"Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy","volume":"10","author":"Cao","year":"2022","journal-title":"biomark Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"104601","DOI":"10.1016\/j.ebiom.2023.104601","article-title":"Towards an optimal model for gastric cancer peritoneal metastasis: current challenges and future directions","volume":"92","author":"Li","year":"2023","journal-title":"EBioMedicine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28373","article-title":"Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors","volume":"134","author":"Thomassen","year":"2014","journal-title":"Int J cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0008","article-title":"Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Ajani","year":"2022","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00492-2","article-title":"Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm","volume":"18","author":"Nakamura","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"188549","DOI":"10.1016\/j.bbcan.2021.188549","article-title":"HER2-targeted therapies in gastric cancer","volume":"1876","author":"Zhu","year":"2021","journal-title":"Biochim Biophys Acta Rev cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02331","article-title":"Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline","volume":"41","author":"Shah","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1967080","DOI":"10.1080\/21688370.2021.1967080","article-title":"Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials","volume":"10","author":"Kyuno","year":"2022","journal-title":"Tissue barriers"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet (London England)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12516","article-title":"The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (London England)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1523096","DOI":"10.1080\/2162402X.2018.1523096","article-title":"Characterization of zolbetuximab in pancreatic cancer models","volume":"8","author":"T\u00fcreci","year":"2019","journal-title":"Oncoimmunology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10555-011-9283-2","article-title":"How to improve the immunogenicity of chemotherapy and radiotherapy","volume":"30","author":"Ma","year":"2011","journal-title":"Cancer metastasis Rev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2219591","DOI":"10.1080\/2162402X.2023.2219591","article-title":"Trial watch: chemotherapy-induced immunogenic cell death in oncology","volume":"12","author":"Sprooten","year":"2023","journal-title":"Oncoimmunology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.21037\/jgo-24-743","article-title":"Expression of Claudin18.2 in metastatic lesions in peritoneum of gastric cancer","volume":"16","author":"Saito","year":"2025","journal-title":"J gastrointestinal Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1641424\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:21:57Z","timestamp":1763446917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1641424\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2025.1641424"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1641424","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"article-number":"1641424"}}